BACKGROUND: Development an effective vaccine against @entity7822 coronavirus (MERS-CoV) is urgent and limited information is available on vaccination in nonhuman primate (NHP) model. We herein report of evaluating a recombinant receptor-binding domain (rRBD) protein vaccine in a @entity2608 model. METHODS: Nine monkeys were randomly assigned to high-dose, low-dose and mock groups,which were immunized with different doses of rRBD plus alum adjuvant or adjuvant alone at different time points (0, 8, 25  weeks). Immunological analysis was conducted after each immunisation. Monkeys were challenged with MERS-CoV at 14  days after the final immunisation followed by observation for clinical signs and chest X-rays. Nasal, oropharyngeal and rectal swabs were also collected for analyses. Monkeys were euthanized 3  days after challenge and multiple specimens from tissues were collected for pathological, virological and immunological tests. CONCLUSION: Robust and sustained immunological responses (including neutralisation antibody) were elicited by the rRBD vaccination. Besides, rRBD vaccination alleviated @entity55 with evidence of reduced tissue impairment and clinical manifestation in monkeys. Furthermore, the rRBD vaccine decreased viral load of lung, @entity825 and oropharyngeal swabs of monkeys. These data in NHP paves a way for further development of an effective @entity1 vaccine against @entity7822 .

Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in XXXX Against Middle East Respiratory Syndrome Coronavirus Challenge.

@entity1 :: ('9606', 'Species') :: ['human'] @entity825 :: ('MESH:D055090', 'Disease') :: ['trachea'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia'] @entity7822 :: ('MESH:D018352', 'Disease') :: ['MERS-CoV infection', 'Middle East respiratory syndrome'] @entity2608 :: ('9544', 'Species') :: ['rhesus macaque']
@entity2608 :: (9544,Species) :: ['Rhesus Macaques']
